QNCX Quince Therapeutics, Inc.

CIK 0001662774 50 ready 8-Ks latest June 26, 2026, 4:31 PM ET RSS · JSON

Activity: NORMAL 3 filings / 30d vs 2 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 50

Latest filing June 26, 2026, 4:31 PM ET

Top materiality 1.00

Event mix other_material ×22 · leadership ×11 · m_and_a ×5

Sentiment 9 pos · 12 neg · 29 neu

Latest earnings reported 2025-Q3

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for QNCX

Highest-materiality recent filing

Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts

May 18, 2026, 9:33 AM ET M&A materiality 1.00 neutral item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2◈ Governance Changes◈ M&A Transactions

Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.

Read filing →

June 26, 2026, 4:31 PM ET other material materiality 0.50 neutral item 3.03

Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026

Reverse stock split ratio set at 1-for-20, approved by board after stockholder authorization.
June 26, 2026, 9:18 AM ET other material materiality 0.50 neutral item 3.03 item 5.03 item 9.01

Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026

Stockholders approved reverse split on June 11, 2026; board set ratio at 1-for-20.
June 11, 2026, 5:06 PM ET other materiality 0.50 neutral item 5.07 ◈ Shareholder Votes ×5

Quince Therapeutics stockholders approve reverse stock split at 1:10 to 1:100 ratio

Reverse stock split approved with 4,715,574 for, 1,517,896 against, 21,866 abstentions.
May 21, 2026, 5:06 PM ET regulatory materiality 0.20 positive item 8.01

Quince Therapeutics regains Nasdaq listing compliance via equity alternative

Company had been notified of MVLS deficiency on March 17, 2026.
May 18, 2026, 4:20 PM ET other material materiality 0.75 positive item 7.01 item 9.01

Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%

Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.
May 18, 2026, 9:33 AM ET M&A materiality 1.00 neutral item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2◈ Governance Changes◈ M&A Transactions

Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts

Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
April 28, 2026, 7:59 PM ET other material materiality 0.30 neutral item 8.01

Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency

Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).
April 22, 2026, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

Quince Therapeutics appoints June Bray as independent director, expands board to four members

June Bray appointed as Class I director effective April 22, 2026, filling a vacancy on the four-member board.
April 9, 2026, 7:59 PM ET other material materiality 0.40 neutral item 3.03 item 5.03 item 9.01 ◈ Equity Issuances◈ Governance Changes

Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026

Approximately 16.3M shares outstanding post-split; ratio 1-for-10.
March 30, 2026, 7:59 PM ET debt materiality 0.75 positive item 1.02 item 7.01 item 9.01 ◈ Material Agreements

Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang

Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.
March 20, 2026, 7:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods

Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.
February 12, 2026, 6:59 PM ET other material materiality 0.90 negative item 2.02 item 8.01

Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger

As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.
February 2, 2026, 6:59 PM ET leadership materiality 0.70 negative item 5.02

Five directors resign from Quince Therapeutics board effective immediately

Directors Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray resigned on Jan 30, 2026.
January 29, 2026, 6:59 PM ET other material materiality 0.85 negative item 9.01

Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted

Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.
November 12, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data

Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.
October 17, 2025, 7:59 PM ET other material materiality 0.55 negative item 7.01

Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T

Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.
September 26, 2025, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 2.03

Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026

Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.
August 11, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M

Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.
July 16, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 8.01 item 9.01

Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026

Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.
June 13, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 9.01

Quince raises $11.5M in private placement of stock and warrants; management participates

Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.
June 5, 2025, 7:59 PM ET other material materiality 0.30 neutral item 5.07

Quince Therapeutics shareholders approve reverse stock split and authorized share increase

Reverse stock split at 1-for-10 ratio approved (28,083,296 for vs 3,309,927 against).
May 13, 2025, 7:59 PM ET other material materiality 0.75 neutral item 2.02 item 9.01

Quince may end Phase 3 NEAT enrollment early in June 2025 to align cash runway with topline results in early 2026

63 participants enrolled to date (56 in primary analysis population ages 6–9); original target was 86.
March 24, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment

Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.
November 14, 2024, 6:59 PM ET other material materiality 0.60 positive item 8.01

Quince Therapeutics regains Nasdaq minimum bid price compliance; delisting risk removed

On Nov 12, 2024, Nasdaq confirmed Quince regained compliance with $1.00 minimum bid price rule.
November 13, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients

Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.
August 13, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Quince Therapeutics Q2 net loss $27.7M; Phase 3 NEAT on track for Q4 2025 topline

Cash $59.4M at June 30; expects runway into 2026 through Phase 3 NEAT topline results.
June 21, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01

Quince Therapeutics receives Nasdaq delisting notice for bid price non-compliance

Received Nasdaq notice for non-compliance with $1.00 minimum bid price requirement.
June 6, 2024, 7:59 PM ET other material materiality 0.30 neutral item 5.07

Quince Therapeutics shareholders approve reverse stock split and elect three directors

Approved 1-for-10 reverse stock split with 31,461,878 votes for, 1,019,669 against, 78,724 abstentions.
February 15, 2024, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 ◈ executive_change

Quince Therapeutics appoints Rajiv Patni as Class III director

Rajiv Patni appointed to board effective Feb 15, 2024 as Class III director, term through 2025 annual meeting.
January 29, 2024, 6:59 PM ET other material materiality 0.50 neutral item 5.02

Quince Therapeutics no salary increase for 2024; option grants to officers

No salary increase for executive officers in 2024; Committee approved stock option grants.
January 5, 2024, 6:59 PM ET M&A materiality 0.70 neutral item 9.01

Quince provides EryDel historical financials; FY2022 loss of €12.5M

EryDel net loss of €12.5M in 2022 vs. €17.3M in 2021; accumulated deficit €76.5M.
January 3, 2024, 6:59 PM ET other material materiality 0.50 positive item 8.01

Quince Therapeutics regains Nasdaq minimum bid price compliance

Nasdaq notified Quince on Dec 4, 2023 of non-compliance due to bid price below $1.00 for 30 consecutive days.
December 22, 2023, 6:59 PM ET other material materiality 0.60 negative item 1.02 ◈ Material Agreements

Quince Therapeutics terminates exclusive worldwide license for NOV004 bone fracture repair program

Termination effective October 31, 2023, following prior decision to discontinue internal development of NOV004.
December 8, 2023, 6:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Quince Therapeutics receives Nasdaq bid price deficiency notice; has until June 3, 2024 to regain compliance

Received Nasdaq notice on Dec 4, 2023 for failing minimum bid price of $1.00 for 30 consecutive trading days.
October 26, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Quince Therapeutics appoints Brendan Hannah as COO, effective Oct 24, 2023

Brendan Hannah, age 38, appointed COO; continues as Chief Business Officer and principal financial/accounting officer.
October 23, 2023, 7:59 PM ET M&A materiality 0.70 positive item 1.01 item 2.01 item 2.03 item 5.02 item 9.01 ◈ Debt Financings◈ executive_change◈ M&A Transactions◈ Material Agreements

Quince Therapeutics closes acquisition of EryDel for up to $485M in milestones

Issued 6,525,315 shares (15.2% ownership) to EryDel shareholders; up to 725,036 more shares at first anniversary.
September 6, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 1.01 item 2.03 item 5.02 ◈ Debt Financings◈ executive_change

Appoints Charles S. Ryan as President; subsidiary issues up to $1M promissory note to EryDel S.p.A.

Promissory note of up to $1.0M to EryDel S.p.A. in two tranches: $500k at 5.07% per annum; second $500k at AFR.
August 10, 2023, 7:59 PM ET leadership materiality 0.55 negative item 5.02 ◈ executive_change

Quince Therapeutics CMO Karen Smith to depart effective Sept 1, 2023

Chief Medical Officer Karen Smith, M.D., Ph.D. will depart on September 1, 2023.
July 24, 2023, 7:59 PM ET M&A materiality 0.85 positive item 1.01 item 2.02 item 2.03 item 3.02 item 5.02 item 7.01 item 8.01 item 9.01 ◈ executive_change ×2◈ Debt Financings◈ Material Agreements

Quince Therapeutics to acquire EryDel for up to 7.25M shares + $485M milestones

EryDel shareholders get up to 7,250,352 shares (16.7% of combined company) and up to $485M in milestone cash payments, no royalties.
May 25, 2023, 7:59 PM ET other material materiality 0.35 neutral item 5.07 ◈ Shareholder Votes ×4

Quince Therapeutics shareholders approve 1-for-10 reverse stock split and elect directors at annual meeting

Shareholders approved 1-for-10 reverse stock split: 22.3M votes for, 4.0M against.
April 5, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Quince Therapeutics adopts one-year poison pill after unsolicited bid, share accumulation

Rights plan effective immediately, expires April 5, 2024; dividend of one right per share on April 17, 2023.
March 28, 2023, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Quince Therapeutics director Philip Low resigns from Board

Director Philip Low, Ph.D. resigned from the Board effective March 27, 2023.
March 3, 2023, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change ×2

Quince Therapeutics appoints Brendan Hannah as principal financial officer after Ted Monohon resigns

Ted Monohon resigns as Chief Accounting Officer and VP of Finance, effective March 16, 2023; no disagreement with company.
January 30, 2023, 6:59 PM ET other material materiality 0.70 neutral item 2.02 item 2.05 item 8.01 ◈ Earnings Releases◈ Restructurings & Charges

Quince Therapeutics cuts workforce 47%; reports $94M cash; pivots to in-licensing

Preliminary unaudited cash, cash equivalents, and marketable securities of ~$94M as of Dec 31, 2022.
January 27, 2023, 6:59 PM ET M&A materiality 0.75 neutral item 1.01 item 5.02 ◈ Material Agreements

Quince Therapeutics sells protease inhibitor portfolio to Lighthouse Pharma for up to $150M milestones

Received 7.5% of Lighthouse common stock; eligible for up to $150M in milestone payments.
December 16, 2022, 6:59 PM ET regulatory materiality 0.80 negative item 3.01 ◈ Listing & Compliance Notices

Quince Therapeutics receives Nasdaq bid price deficiency notice; 180-day cure period.

Notice on Dec 13, 2022: closing bid price below $1.00 for 30 consecutive days.
September 30, 2022, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

Quince Therapeutics director Marwan Sabbagh resigns effective Sept 30, 2022

Dr. Marwan Sabbagh resigned from the Board effective September 30, 2022; no disagreement with company.
August 1, 2022, 7:59 PM ET other material materiality 0.65 neutral item 2.02 item 5.03 item 8.01 item 9.01

Cortexyme rebrands as Quince Therapeutics, shifts to bone-targeting drugs, reports $105M cash

Cash, cash equivalents and short-term investments: ~$105M as of June 30, 2022 (preliminary).
July 22, 2022, 7:59 PM ET leadership materiality 0.65 negative item 5.02 ◈ executive_change

Cortexyme EVP of R&D Leslie Holsinger resigns effective July 31, 2022

Dr. Holsinger receives $339,000 cash severance (9 months' base salary) in a lump sum.
June 10, 2022, 7:59 PM ET leadership materiality 0.70 negative item 1.01 item 2.03 item 5.02 item 5.07 ◈ executive_change ×4

CFO/COO and director Christopher Lowe resigns; June Bray appointed director; Monohon named PFO

Christopher Lowe resigned as board member (June 8) and as CFO/COO (effective June 10); separation includes $354,750 cash severance and equity acceleration.